When considering drug dosing for an efficient combination therapy, REG administered at 3 mg/kg induced only moderate tumor growth inhibition in the subcutaneous MC38 model, but the anti-tumor activity was significantly enhanced in combination with aPD1. Here, REG1A is linked to neoplasm.